Delivery of Manganese Carbonyl to the Tumor Microenvironment using Tumor-Derived Exosomes for Cancer Gas Therapy and Low Dose Radiotherapy

Biomaterials ◽  
2021 ◽  
pp. 120894
Author(s):  
Daoming Zhu ◽  
Zeming Liu ◽  
Yang Li ◽  
Qinqin Huang ◽  
Ligang Xia ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Low Dose ◽  
Low Dose Radiotherapy ◽  
Manganese Carbonyl

scholarly journals Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases

2021 ◽  
Vol 12 ◽  
Author(s):  
Kewen He ◽  
Hampartsoum B. Barsoumian ◽  
Genevieve Bertolet ◽  
Vivek Verma ◽  
Carola Leuschner ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Liver Metastases ◽  
Low Dose ◽  
Hepatic Metastases ◽  
Complete Response ◽  
Tumor Control ◽  
T Cell Therapy ◽  
Immune Resistance ◽  
Low Dose Radiotherapy ◽  
Recent Case Study

Despite multiple therapeutic approaches, the presence of liver metastases carries a guarded prognosis, urgently necessitating further clinical and scientific research to develop curative interventions. The liver is an immunoprivileged organ that suppresses the effectiveness of immunotherapies in patients with hepatic metastases. Cancer immunotherapies have been successfully bolstered by low-dose radiotherapy (LDRT), which is capable of reprogramming the tumor microenvironment (TME) from an immunosuppressive to an immunostimulatory one. Likewise, LDRT may be able to revoke the immune privilege enjoyed by the liver, permitting successful immunotherapies there. Here, we first review challenges that face the treatment of liver metastases. We next outline emerging preclinical and clinical evidence supporting enhanced systemic tumor control of LDRT in the context of cancer immunotherapy. Finally, we will discuss the rationale of combining liver-directed LDRT with immunostimulatory strategies to overcome immune resistance and achieve better clinical response. This notion is supported by a recent case study in which a patient who had progressed following T cell therapy experienced a complete response after LDRT to the liver.

scholarly journals Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?

Dose-Response ◽  
2020 ◽  
Vol 18 (3) ◽  
pp. 155932582095135
Author(s):  
Michael I. Koukourakis
Keyword(s):  
Respiratory Failure ◽  
Immune Cells ◽  
Late Stage ◽  
Low Dose ◽  
Inflammatory Cells ◽  
Lung Parenchyma ◽  
Death Rates ◽  
Low Dose Radiotherapy ◽  
Therapeutic Value ◽  
Inflammatory Effect

Low dose radiotherapy has been used in the pre-antibiotic era for the treatment of all kind of pneumonia, with relative success. The unimaginable daily death toll of thousands of victims dying from COVID-19 pneumonia and the marginal therapeutic value of agents tested, brings forward the re-evaluation of the position of radiotherapy in the treatment of late stage lethal COVID-induced respiratory failure. A sound biological rationale supports this idea. Immunopathology studies show that excessive inflammation and infiltration of the lung parenchyma by immune cells is the cause of death. Mice lacking IFNαβ receptors remain unaffected by the virus. Radiotherapy at doses of 50-200cG may exert an intense anti-inflammatory effect and reduce the burden of inflammatory cells infiltrating the lungs. Whether radiotherapy, in conjunction with remdesivir and/or macrolides can reduce the dramatic death rates related to COVID-19 is an open challenge, under the absence of an alternative solution.

Clinically derived dose–effect relationship for hyperthermia given in combination with low-dose radiotherapy

1986 ◽  
Vol 59 (697) ◽  
pp. 81-82 ◽  
Author(s):  
J. van der Zee ◽  
G. C. van Rhoon ◽  
J. L. Wike-Hooley ◽  
H. S. Reinhold
Keyword(s):  
Low Dose ◽  
Dose Effect ◽  
Effect Relationship ◽  
Low Dose Radiotherapy

Successful low-dose radiotherapy treatment for Kasabach-Merritt syndrome

2016 ◽  
Vol 58 (10) ◽  
pp. 1084-1086 ◽  
Author(s):  
Shohei Yamamoto ◽  
Kosuke Akiyama ◽  
Ryota Kaneko ◽  
Mayumi Hayashi ◽  
Daisuke Toyama ◽  
...  
Keyword(s):  
Low Dose ◽  
Low Dose Radiotherapy ◽  
Radiotherapy Treatment

Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks

2010 ◽  
Vol 78 (4) ◽  
pp. 975-982 ◽  
Author(s):  
Gérard Ganem ◽  
Guillaume Cartron ◽  
Théodore Girinsky ◽  
Rick L.M. Haas ◽  
Jean Marc Cosset ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Low Dose ◽  
Clinical Results ◽  
Mechanisms Of Action ◽  
Low Dose Radiotherapy

scholarly journals Spinal cord compression in b-thalassemia: follow-up after radiotherapy

1998 ◽  
Vol 116 (6) ◽  
pp. 1879-1881 ◽  
Author(s):  
Silvana Fahel da Fonseca ◽  
Maria Stella Figueiredo ◽  
Rodolfo Delfini Cançado ◽  
Fernando Nakandakare ◽  
Roberto Segreto ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Case Report ◽  
Spinal Cord Compression ◽  
Low Dose ◽  
Extramedullary Hematopoiesis ◽  
Cord Compression ◽  
Hematologic Disorders ◽  
Rare Syndrome ◽  
Low Dose Radiotherapy

CONTEXT: Spinal cord compression due to extramedullary hematopoiesis is a well-described but rare syndrome encountered in several clinical hematologic disorders, including <FONT FACE="Symbol">b</font>-thalassemia. CASE REPORT: We report the case of a patient with intermediate <FONT FACE="Symbol">b</font>-thalassemia and crural paraparesis due to spinal cord compression by a paravertebral extramedullary mass. She was successfully treated with low-dose radiotherapy and transfusions. After splenectomy, she was regularly followed up for over four years without transfusion or recurrence of spinal cord compression. DISCUSSION: Extramedullary hematopoiesis should be investigated in patients with hematologic disorders and spinal cord symptoms. The rapid recognition and treatment with radiotherapy can dramatically alleviate symptoms.

Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice

2006 ◽  
Vol 66 (2) ◽  
pp. 560-567 ◽  
Author(s):  
Meritxell Arenas ◽  
Fèlix Gil ◽  
Meritxell Gironella ◽  
Víctor Hernández ◽  
Sandra Jorcano ◽  
...  
Keyword(s):  
Experimental Model ◽  
Systemic Inflammation ◽  
Low Dose ◽  
Low Dose Radiotherapy ◽  
Anti Inflammatory

scholarly journals Low-Dose Radiotherapy Has No Harmful Effects on Key Cells of Healthy Non-Inflamed Joints

2018 ◽  
Vol 19 (10) ◽  
pp. 3197 ◽  
Author(s):  
Lisa Deloch ◽  
Michael Rückert ◽  
Rainer Fietkau ◽  
Benjamin Frey ◽  
Udo Gaipl
Keyword(s):  
Bone Marrow ◽  
Cell Death ◽  
Low Dose ◽  
Immune Cell ◽  
Bone Marrow Cells ◽  
Positive Impact ◽  
Bone Destruction ◽  
T Cell Subsets ◽  
Low Dose Radiotherapy ◽  
Harmful Effects

Low-dose radiotherapy (LD-RT) for benign inflammatory and/or bone destructive diseases has been used long. Therefore, mechanistic investigations on cells being present in joints are mostly made in an inflammatory setting. This raises the question whether similar effects of LD-RT are also seen in healthy tissue and thus might cause possible harmful effects. We performed examinations on the functionality and phenotype of key cells within the joint, namely on fibroblast-like synoviocytes (FLS), osteoclasts and osteoblasts, as well as on immune cells. Low doses of ionizing radiation showed only a minor impact on cytokine release by healthy FLS as well as on molecules involved in cartilage and bone destruction and had no significant impact on cell death and migration properties. The bone resorbing abilities of healthy osteoclasts was slightly reduced following LD-RT and a positive impact on bone formation of healthy osteoblasts was observed after in particular exposure to 0.5 Gray (Gy). Cell death rates of bone-marrow cells were only marginally increased and immune cell composition of the bone marrow showed a slight shift from CD8+ to CD4+ T cell subsets. Taken together, our results indicate that LD-RT with particularly a single dose of 0.5 Gy has no harmful effects on cells of healthy joints.

Sign in / Sign up

Export Citation Format

Share Document